WO2022177269A1 - 넌센스-매개 mrna 분해를 억제하기 위한 화합물 - Google Patents
넌센스-매개 mrna 분해를 억제하기 위한 화합물 Download PDFInfo
- Publication number
- WO2022177269A1 WO2022177269A1 PCT/KR2022/002228 KR2022002228W WO2022177269A1 WO 2022177269 A1 WO2022177269 A1 WO 2022177269A1 KR 2022002228 W KR2022002228 W KR 2022002228W WO 2022177269 A1 WO2022177269 A1 WO 2022177269A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nmd
- compound
- ptc
- disease
- pharmaceutical composition
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 96
- 108020004999 messenger RNA Proteins 0.000 title claims abstract description 40
- 230000001404 mediated effect Effects 0.000 title claims abstract description 10
- 230000002401 inhibitory effect Effects 0.000 title abstract description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 52
- 201000010099 disease Diseases 0.000 claims abstract description 46
- 150000003839 salts Chemical class 0.000 claims abstract description 37
- 108020004485 Nonsense Codon Proteins 0.000 claims description 72
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 27
- 208000016361 genetic disease Diseases 0.000 claims description 27
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 21
- 108020004705 Codon Proteins 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 230000037434 nonsense mutation Effects 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 230000026731 phosphorylation Effects 0.000 claims description 10
- 238000006366 phosphorylation reaction Methods 0.000 claims description 10
- 230000037433 frameshift Effects 0.000 claims description 9
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 9
- 208000005980 beta thalassemia Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 230000015556 catabolic process Effects 0.000 claims description 8
- 238000006731 degradation reaction Methods 0.000 claims description 8
- 231100000221 frame shift mutation induction Toxicity 0.000 claims description 8
- 201000006938 muscular dystrophy Diseases 0.000 claims description 8
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 7
- 208000016356 hereditary diffuse gastric adenocarcinoma Diseases 0.000 claims description 7
- 208000024331 hereditary diffuse gastric cancer Diseases 0.000 claims description 7
- 208000010061 Autosomal Dominant Polycystic Kidney Diseases 0.000 claims description 6
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 claims description 6
- 208000021124 Heritable pulmonary arterial hypertension Diseases 0.000 claims description 6
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 claims description 6
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 6
- 208000006289 Rett Syndrome Diseases 0.000 claims description 6
- 208000033858 Stüve-Wiedemann syndrome Diseases 0.000 claims description 6
- 208000014769 Usher Syndromes Diseases 0.000 claims description 6
- 201000004525 Zellweger Syndrome Diseases 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- 208000022185 autosomal dominant polycystic kidney disease Diseases 0.000 claims description 6
- 208000025014 late infantile neuronal ceroid lipofuscinosis Diseases 0.000 claims description 6
- 201000008105 leukocyte adhesion deficiency 1 Diseases 0.000 claims description 6
- 208000023269 peroxisome biogenesis disease Diseases 0.000 claims description 6
- 201000010384 renal tubular acidosis Diseases 0.000 claims description 6
- 108700005857 Carnitine palmitoyl transferase 1A deficiency Proteins 0.000 claims description 5
- 208000005359 Carnitine palmitoyl transferase 1A deficiency Diseases 0.000 claims description 5
- 206010064571 Gene mutation Diseases 0.000 claims description 5
- 201000004010 carnitine palmitoyltransferase I deficiency Diseases 0.000 claims description 5
- 201000006935 Becker muscular dystrophy Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 108700001666 APC Genes Proteins 0.000 claims description 3
- 206010003594 Ataxia telangiectasia Diseases 0.000 claims description 3
- 206010003658 Atrial Fibrillation Diseases 0.000 claims description 3
- 102100027943 Carnitine O-palmitoyltransferase 1, liver isoform Human genes 0.000 claims description 3
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 3
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 3
- 208000037586 Congenital muscular dystrophy, Ullrich type Diseases 0.000 claims description 3
- 206010011777 Cystinosis Diseases 0.000 claims description 3
- 208000015178 Hurler syndrome Diseases 0.000 claims description 3
- 102100022745 Laminin subunit alpha-2 Human genes 0.000 claims description 3
- 206010056886 Mucopolysaccharidosis I Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 201000006815 congenital muscular dystrophy Diseases 0.000 claims description 3
- 230000007812 deficiency Effects 0.000 claims description 3
- 201000007386 factor VII deficiency Diseases 0.000 claims description 3
- 201000007830 familial atrial fibrillation Diseases 0.000 claims description 3
- 208000009429 hemophilia B Diseases 0.000 claims description 3
- 230000002440 hepatic effect Effects 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 201000005118 Nephrogenic diabetes insipidus Diseases 0.000 claims description 2
- 101000579423 Homo sapiens Regulator of nonsense transcripts 1 Proteins 0.000 claims 1
- 102100028287 Regulator of nonsense transcripts 1 Human genes 0.000 claims 1
- 201000008616 Usher syndrome type 1 Diseases 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 45
- 108090000623 proteins and genes Proteins 0.000 description 39
- 238000011282 treatment Methods 0.000 description 19
- 235000018102 proteins Nutrition 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 18
- 230000000694 effects Effects 0.000 description 13
- 229940125904 compound 1 Drugs 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 230000035772 mutation Effects 0.000 description 11
- 108010069091 Dystrophin Proteins 0.000 description 10
- 108010052090 Renilla Luciferases Proteins 0.000 description 10
- 102000001039 Dystrophin Human genes 0.000 description 8
- 238000013537 high throughput screening Methods 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 7
- 102100021087 Regulator of nonsense transcripts 2 Human genes 0.000 description 7
- 101710028540 UPF2 Proteins 0.000 description 7
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 6
- 102000038030 PI3Ks Human genes 0.000 description 6
- 108091007960 PI3Ks Proteins 0.000 description 6
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 108090000331 Firefly luciferases Proteins 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- -1 that is Proteins 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 4
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 4
- 208000002903 Thalassemia Diseases 0.000 description 4
- 101150025199 Upf1 gene Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 229940125782 compound 2 Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 4
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 108020005345 3' Untranslated Regions Proteins 0.000 description 3
- 208000001454 Anhidrotic Ectodermal Dysplasia 1 Diseases 0.000 description 3
- 206010003591 Ataxia Diseases 0.000 description 3
- 206010010452 Congenital ectodermal dysplasia Diseases 0.000 description 3
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 229960001948 caffeine Drugs 0.000 description 3
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 201000003535 hypohidrotic ectodermal dysplasia Diseases 0.000 description 3
- 208000035128 hypohidrotic/hair/tooth type autosomal recessive ectodermal dysplasia 10B Diseases 0.000 description 3
- 208000032771 hypohidrotic/hair/tooth type autosomal recessive ectodermal dysplasia 11B Diseases 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- CGBJSGAELGCMKE-UHFFFAOYSA-N omipalisib Chemical compound COC1=NC=C(C=2C=C3C(C=4C=NN=CC=4)=CC=NC3=CC=2)C=C1NS(=O)(=O)C1=CC=C(F)C=C1F CGBJSGAELGCMKE-UHFFFAOYSA-N 0.000 description 3
- 230000002028 premature Effects 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 2
- ILBRKJBKDGCSCB-UHFFFAOYSA-N 2-(6,7-dimethoxy-4-quinazolinyl)-5-(2-pyridinyl)-1,2,4-triazol-3-amine Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1N(C(=N1)N)N=C1C1=CC=CC=N1 ILBRKJBKDGCSCB-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- OOUGLTULBSNHNF-UHFFFAOYSA-N 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid Chemical compound OC(=O)C1=CC=CC(C=2N=C(ON=2)C=2C(=CC=CC=2)F)=C1 OOUGLTULBSNHNF-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 102100023457 Chloride channel protein 1 Human genes 0.000 description 2
- 102100029362 Cone-rod homeobox protein Human genes 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 101000906651 Homo sapiens Chloride channel protein 1 Proteins 0.000 description 2
- 101000919370 Homo sapiens Cone-rod homeobox protein Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102100035678 Interferon gamma receptor 1 Human genes 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 208000021642 Muscular disease Diseases 0.000 description 2
- 206010062207 Mycobacterial infection Diseases 0.000 description 2
- 102000055325 Myelin P0 Human genes 0.000 description 2
- 108050003852 Myelin protein P0 Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102000007354 PAX6 Transcription Factor Human genes 0.000 description 2
- 108010032788 PAX6 Transcription Factor Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 108010006700 Receptor Tyrosine Kinase-like Orphan Receptors Proteins 0.000 description 2
- 102100040756 Rhodopsin Human genes 0.000 description 2
- 108090000820 Rhodopsin Proteins 0.000 description 2
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010043391 Thalassaemia beta Diseases 0.000 description 2
- 208000010287 Type 3 von Willebrand Disease Diseases 0.000 description 2
- 102100039616 Tyrosine-protein kinase transmembrane receptor ROR2 Human genes 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 description 2
- 229950006418 dactolisib Drugs 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 208000027531 mycobacterial infectious disease Diseases 0.000 description 2
- 229950008089 omipalisib Drugs 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 108010047303 von Willebrand Factor Proteins 0.000 description 2
- 102100036537 von Willebrand factor Human genes 0.000 description 2
- 229960001134 von willebrand factor Drugs 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- KKFDCBRMNNSAAW-UHFFFAOYSA-N 2-(morpholin-4-yl)ethanol Chemical compound OCCN1CCOCC1 KKFDCBRMNNSAAW-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical class NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 102100037232 Amiloride-sensitive sodium channel subunit beta Human genes 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101100421200 Caenorhabditis elegans sep-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 201000009069 Charcot-Marie-Tooth disease type 4E Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- 102100029117 Coagulation factor X Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 102100033601 Collagen alpha-1(I) chain Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010057042 Congenital cutis laxa Diseases 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108010090310 Ectodysplasin Receptors Proteins 0.000 description 1
- 102100033167 Elastin Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 201000006107 Familial adenomatous polyposis Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 208000034902 Generalized pseudohypoaldosteronism type 1 Diseases 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000740426 Homo sapiens Amiloride-sensitive sodium channel subunit beta Proteins 0.000 description 1
- 101001001420 Homo sapiens Interferon gamma receptor 1 Proteins 0.000 description 1
- 101000738945 Homo sapiens Proline-rich nuclear receptor coactivator 2 Proteins 0.000 description 1
- 101001090928 Homo sapiens Regulator of nonsense transcripts 3B Proteins 0.000 description 1
- 101000864057 Homo sapiens Serine/threonine-protein kinase SMG1 Proteins 0.000 description 1
- 101710174028 Interferon gamma receptor 1 Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 201000003533 Leber congenital amaurosis Diseases 0.000 description 1
- 201000011062 Li-Fraumeni syndrome Diseases 0.000 description 1
- 208000026709 Liddle syndrome Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100149887 Mus musculus Sox10 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 208000010316 Myotonia congenita Diseases 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 101150077232 NMD4 gene Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102100037393 Proline-rich nuclear receptor coactivator 2 Human genes 0.000 description 1
- 208000032225 Proximal spinal muscular atrophy type 1 Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 102100034978 Regulator of nonsense transcripts 3B Human genes 0.000 description 1
- 208000005568 Robinow syndrome Diseases 0.000 description 1
- 101100080124 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) NMD5 gene Proteins 0.000 description 1
- 102100029938 Serine/threonine-protein kinase SMG1 Human genes 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000002220 Supravalvular aortic stenosis Diseases 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 208000010641 Tooth disease Diseases 0.000 description 1
- 102100038808 Transcription factor SOX-10 Human genes 0.000 description 1
- 101710176133 Transcription factor Sox-10 Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 102100030810 Tumor necrosis factor receptor superfamily member EDAR Human genes 0.000 description 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 108010029483 alpha 1 Chain Collagen Type I Proteins 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 208000008303 aniridia Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229960003995 ataluren Drugs 0.000 description 1
- 208000031375 autosomal dominant myotonia congenita Diseases 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229940095643 calcium hydroxide Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
- 229940105756 coagulation factor x Drugs 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 201000010064 diabetes insipidus Diseases 0.000 description 1
- 125000005131 dialkylammonium group Chemical group 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 201000010048 endomyocardial fibrosis Diseases 0.000 description 1
- XBRDBODLCHKXHI-UHFFFAOYSA-N epolamine Chemical compound OCCN1CCCC1 XBRDBODLCHKXHI-UHFFFAOYSA-N 0.000 description 1
- 229940012413 factor vii Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 206010019465 hemiparesis Diseases 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 230000001096 hypoplastic effect Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000008316 intracellular mechanism Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 208000036546 leukodystrophy Diseases 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Inorganic materials [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052751 metal Chemical class 0.000 description 1
- 239000002184 metal Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 230000001123 neurodevelopmental effect Effects 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 208000007750 pseudohypoaldosteronism Diseases 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 150000005621 tetraalkylammonium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 125000005208 trialkylammonium group Chemical group 0.000 description 1
- 150000003628 tricarboxylic acids Chemical class 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 208000032471 type 1 spinal muscular atrophy Diseases 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a compound or a pharmaceutically acceptable salt thereof for inhibiting nonsense-mediated mRNA decay (hereinafter referred to as "NMD").
- NMD nonsense-mediated mRNA decay
- nonsense mutation a mutation generated in the DNA sequence, such as mistakes during DNA recombination and replication, as well as aberrant transcription, inefficient splicing, and frameshift mutations. ) due to abnormal or inefficient intracellular mechanisms.
- mRNAs with nonsense mutations may express proteins shorter than their normal length, thereby inhibiting the normal function of cells.
- the NMD mechanism which is a quality inspection mechanism that exists in the cell, and are removed from the cell at a much faster rate than normal mRNA. That is, cells can selectively recognize/remove erroneous mRNAs that can harm themselves by using the NMD mechanism.
- NMD-related diseases such as Duchenne muscular dystrophy (DMD)
- drug development such as PTC 124 (generic name: ataluren)
- PTC 124 gene: ataluren
- 1,2,4-oxidiazole compound a 1,2,4-oxidiazole compound
- One object of the present invention is to provide a compound that effectively inhibits NMD (hereinafter also referred to as "NMD inhibitory compound”), thereby providing a pharmaceutical composition that can be used for the prevention or treatment of NMD-related genetic diseases comprising the same as an active ingredient will do
- Another object of the present invention is to provide the use of the NMD inhibitory compound for the prevention or treatment of NMD-related genetic diseases.
- Another object of the present invention is to provide a method for preventing or treating an NMD-associated genetic disease in a subject in need thereof by administering an effective amount of an NMD inhibitory compound to the subject.
- the NMD inhibitory compound of the present invention reduces NMD efficiency, it can be effectively used for the prevention or treatment of various diseases caused by NMD caused by PTC, in particular, genetic diseases.
- FIG. 1 is a schematic diagram illustrating a cell line that always expresses an NMD target mRNA (constitutive expression) for high-throughput screening (HTS) of an NMD inhibitor.
- Figure 2 shows the results of treating the cell line of Figure 1, which is a non-specific NMD inhibitor, caffeine.
- FIG. 3 shows the results of treating the cell line of FIG. 1 with wortmannin, a non-specific NMD inhibitor.
- FIG. 4 shows the results of confirming the luciferase (renilla luciferase; RLuc) expression efficiency at the mRNA and protein levels after treatment of compounds 1 to 3 in the cell line of FIG. 1 .
- luciferase renilla luciferase
- FIG. 7 is a schematic diagram of a method for artificially reducing the amount of reporter mRNA by artificially tethering the proteins (Upf1, Upf2, Upf3X) acting in each step of NMD to the 3' UTR of the reporter mRNA. This method allows one to determine the exact step of a particular compound on NMD.
- FIG. 8 shows the results of checking the level of ⁇ -6bs mRNA, which is a reporter mRNA, after each cell line was treated with Compound 1 or 3 using the method of FIG. 7 .
- FIG. 9 shows the results of confirming the level of ⁇ -6bs mRNA, which is a reporter mRNA, after each cell line was treated with Compound 1 or 2 using the method of FIG. 7 .
- Figure 10 shows the results of confirming the mRNA level of the NMD target gene dystrophin gene after each treatment of compounds 1 to 3 in cells derived from a patient with Duchenne muscular dystrophy.
- the present invention relates to a pharmaceutical composition for preventing or treating nonsense-mediated mRNA degradation (NMD)-related diseases, comprising a compound represented by any one of the following Chemical Formulas 1 to 3 or a pharmaceutically acceptable salt thereof as an active ingredient; the use of the compound or a pharmaceutically acceptable salt thereof for the prophylaxis or treatment of an NMD-related disease; Or, it provides a method for preventing or treating NMD-related diseases, comprising administering the compound or a pharmaceutically acceptable salt thereof to a subject in need thereof.
- NMD nonsense-mediated mRNA degradation
- the NMD-related disease may be related to a mutant gene comprising a nonsense mutation, or may be a genetic disease caused by NMD due to an immature stop codon (PTC) associated with a nonsense mutation or a frameshift mutation.
- PTC immature stop codon
- the NMD-related genetic disease is cystic fibrosis, muscular dystrophy (eg, Duchenne muscular dystrophy, Becker muscular dystrophy), Ullrich's disease, congenital muscular dystrophy, or large muscle dystrophy, etc.), autosomal dominant polycystic kidney disease (ADOKD), ataxia telangiectasia, beta-thalassemia, factor VII deficiency (factor VII) deficiency), familial atrial fibrillation, hemophilia B, hepatic carnitine palmitoyltransferase 1A deficiency (CPT1A), heritable pulmonary arterial hypertension (HPAH), late infantile neurogenic ceroid lipofu Late infantile neuronal ceroid lipofuscinosis (LNCL), leukocyte adhesion deficiency 1 (LAD1), methylmalonic academia (MMA), Hurler syndrome, nephropatic cystinosis, Obesity, peroxisome biogenesis disorder (PBD), renal tubular
- the NMD-related diseases of the present invention include, in addition to the above-mentioned NMD-related genetic diseases, various cancers caused by the presence of an immature stop codon (eg, hereditary diffuse gastric cancer (HDGC), P53 gene mutations). cancer associated with APC gene mutation).
- an immature stop codon eg, hereditary diffuse gastric cancer (HDGC), P53 gene mutations.
- HDGC hereditary diffuse gastric cancer
- P53 gene mutations cancer associated with APC gene mutation.
- the present invention provides a compound for inhibiting NMD, or a pharmaceutically acceptable salt thereof.
- the compound for inhibiting NMD of the present invention is represented by the following formula (1).
- the compound of Formula 1 is also referred to simply as “Compound 1”.
- the compound of Formula 1 is named by the code number of GSK2126458 or the generic name of Omipalisib, and its compound name is 2,4-Difluoro-N- ⁇ 2- (methyloxy)-5-[4-(4-pyridazinyl) )-6-quinolinyl]-3-pyridinyl ⁇ benzenesulfonamide.
- the compound of Formula 1 is known to exhibit anticancer effects by binding to PI3K in the PI3K/mTOR signaling pathway and inhibiting PI3K (https://pubchem.ncbi.nlm.nih.gov/compound/Omipalisib).
- the preparation of compound 1 and its use are disclosed in WO 2008/144463, in particular Example 345, and the like.
- the compound for inhibiting NMD of the present invention is represented by the following formula (2).
- the compound of formula (2) is also referred to simply as "compound 2”.
- the compound of Formula 2 is named as the code number of BEZ235 or the generic name of Dactolisib, and its compound name is 2-Methyl-2- ⁇ 4-[3-methyl-2-oxo-8-(quinolin-3) -yl)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl]phenyl ⁇ propanenitrile.
- the compound for inhibiting NMD of the present invention is represented by the following formula (3).
- the compound of formula (3) is also referred to simply as "compound 3".
- the compound of Formula 3 is named with the code number of CP-466722, and its compound name is 1-(6,7-Dimethoxy-4-quinazolinyl)-3-(2-pyridinyl)-1H-1,2,4-Triazol- 5-amine.
- each of the compounds of Formulas 1 to 3 may be collectively referred to as “compounds of the present invention”.
- the compounds of the present invention may exist in the form of pharmaceutically acceptable salts.
- “Pharmaceutically acceptable salt” or “salt” is used herein to refer to an acid or base addition salt suitable or compatible with the treatment of a patient.
- exemplary inorganic acids that form suitable salts include hydrochloric acid, hydrobromic acid, sulfuric acid and phosphoric acid, as well as metal salts such as sodium monohydrogen orthophosphate and potassium hydrogen sulfate.
- Exemplary organic acids that form suitable salts include mono-, di- and tricarboxylic acids such as glycolic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, malic acid, tartaric acid, citric acid, ascorbic acid, maleic acid acids, benzoic acid, phenylacetic acid, cinnamic acid and salicylic acid, as well as sulfonic acids such as p-toluenesulfonic acid and methanesulfonic acid.
- Monoacid or diacid salts may be formed, and such salts may exist in hydrated, solvated or substantially anhydrous form.
- acid addition salts of compounds of the present invention are more soluble in water and various hydrophilic organic solvents and generally exhibit higher melting points compared to their free base form.
- the selection of an appropriate salt is known to the person skilled in the art.
- Other non-pharmaceutically acceptable salts, such as oxalates, can be used in the isolation of compounds of the invention, for example, for laboratory use or for subsequent conversion to pharmaceutically acceptable acid addition salts.
- Exemplary inorganic bases that form suitable salts include lithium, sodium, potassium, calcium, magnesium, or barium hydroxide.
- Exemplary organic bases that form suitable salts include aliphatic, cycloaliphatic or aromatic organic amines such as methylamine, trimethylamine and picoline or ammonia.
- contemplated salts of the present invention include alkyl, dialkyl, trialkyl or tetra-alkyl ammonium salts.
- contemplated salts of the present invention include L-arginine, benentamine, benzathine, betaine, calcium hydroxide, choline, theanol, diethanolamine, diethylamine, 2-(diethylamino)ethanol; Ethanolamine, ethylenediamine, N-methylglucamine, hydrabamine, 1H-imidazole, lithium, L-lysine, magnesium, 4-(2-hydroxyethyl)morpholine, piperazine, potassium, 1-(2- hydroxyethyl)pyrrolidine, sodium, triethanolamine, tromethamine, and zinc salts.
- the compound of Formula 2 may exist in the form of tosylate.
- the compounds of the present invention also include, without limitation, all possible optical isomers as well as pharmaceutically acceptable salts thereof.
- Stereoisomers of the compounds of the present invention can be prepared using methods known in the art.
- the compounds of the present invention may be prepared in crystalline or amorphous form.
- the compound When the compound is prepared in crystalline form, it may optionally be hydrated or solvated.
- the compounds of the present invention may be formulated as any therapeutic pharmaceutical composition, or in a form suitable for use in any of the methods disclosed herein, such as prophylactic or therapeutic methods.
- a compound of the present invention as an active ingredient of a therapeutic agent includes any pharmaceutically acceptable salts thereof, all of which are to be considered to be included within the scope of the present invention. For convenience of explanation, it may be simply abbreviated as a compound of the above formula or a compound of the present invention.
- compounds of the present invention may inhibit nonsense-mediated mRNA degradation (NMD). Accordingly, compounds 1 to 3 of the present invention exhibit an effect of preventing or treating NMD-related diseases.
- the present invention relates to a pharmaceutical composition for the prevention or treatment of NMD-related diseases, comprising as an active ingredient a compound of the present invention or a pharmaceutically acceptable salt thereof.
- the compound or a pharmaceutically acceptable salt thereof may be included in an effective amount.
- the present invention relates to the use of a compound of the present invention, or a pharmaceutically acceptable salt thereof, for the prevention or treatment of a disease associated with NMD.
- the present invention relates to a method for preventing or treating a disease associated with NMD, comprising administering to a subject in need thereof a compound of the present invention, or a pharmaceutically acceptable salt thereof.
- the compound or a pharmaceutically acceptable salt thereof may be administered in a therapeutically effective amount.
- the terms “effective amount” or “therapeutically effective amount” are used interchangeably herein and refer to an amount of a compound, formulation, substance or composition effective to achieve a particular biological result as described herein.
- therapeutically effective amount refers to a biological or medical response of a subject, for example, alleviating symptoms, alleviating a condition, slowing or delaying the progression of a disease, preventing a disease, etc. The amount of the compound of the present invention is indicated.
- the term “subject” or “patient” includes humans and non-human animals.
- Non-human animals include vertebrates, such as mammals and non-mammals, such as non-human primates, sheep, cats, horses, cattle, chickens, dogs, mice, rats, goats, rabbits, and pigs.
- the subject is a human.
- the terms "patient” or “subject” are used interchangeably herein.
- the term “treat”, “treating” or “treatment” of any disease, condition or disorder refers to alleviating or ameliorating the disease, condition or disorder (ie, the condition or clinical symptoms thereof). delaying or arresting the occurrence of at least one of the following); or ameliorating or ameliorating at least one physical parameter or biomarker associated with a disease, condition or disorder, including those not recognized by the patient.
- the term “prevent”, “preventing” or “prevention” of any disease, condition or disorder includes prophylactic treatment of the disease, condition or disorder; or delaying the onset or progression of a condition or disorder.
- the NMD-associated disease may be a disease responsive to NMD inhibition.
- the NMD-associated disease may be associated with a mutant gene comprising a nonsense mutation, for example, a genetic disease caused by a nonsense mutation.
- the NMD-associated disease may be a genetic disease caused by NMD due to an immature stop codon (PTC) associated with a nonsense mutation or a frameshift mutation.
- PTC immature stop codon
- the NMD-related disease of the present invention may be selected based on the nucleotide sequence of a gene having PTC.
- NMD nonsense-mediated RNA degradation
- PTC immature stop codon
- NMD monitoring mechanisms reduce or prevent the formation of these defective proteins and peptides.
- About one-third of all genetic diseases and some forms of cancer are known to be caused by nonsense or frameshift mutations that introduce PTC, and NMD may modulate the clinical phenotype of these diseases. Accordingly, modulation of NMD (ie, inhibition or increase of NMD) may offer potential therapeutic benefits.
- premature translation termination refers to the result of a mutation that changes a codon corresponding to an amino acid to a stop codon
- premature termination codon PTC
- premature stop codon refers to a change in a codon corresponding to an amino acid to a stop codon
- nonsense mutation is a point mutation that changes a codon corresponding to an amino acid to a stop codon.
- frameshift mutation refers to a genetic mutation caused by a deletion or insertion of a DNA sequence that shifts in the direction in which the sequence is read.
- NMD inhibition refers to reduced activity of NMD and reduced degradation of defective mRNA in a cell by any measurable amount as compared to a cell without NMD inhibition.
- NMD inhibition blocks the function of a protein component of the NMD pathway, inhibits translation, or allows the translation machine to bypass the immature stop codon ("translational bypass therapy (TBT)" or "read-through”). -through)”), etc. (see, for example, Bashyam, Recent Patents on DNA & Gene Sequences 2009, 3, 7-15).
- the compound of the present invention may act on any of the proteins (UPF1, UPF2, UPF3X, eIF4AIII, PNRC2, etc.) acting on each step of NMD or on any step in which they are involved.
- the compounds of the present invention can inhibit the efficiency of NMD by targeting UPF1, which is an important factor in NMD.
- the compound of the present invention exhibits an NMD inhibitory effect by inhibiting the binding of UPF1 and UPF2, which are major proteins of NMD.
- the compound of the present invention exhibits an NMD inhibitory effect by inhibiting UPF1 phosphorylation, a major step in NMD.
- compound 3 exhibits an NMD inhibitory effect by targeting a step prior to UPF1.
- NMD-associated disease refers to a disease responsive to NMD inhibition, in which the disease phenotype is reduced by NMD inhibition. Patients with this disease phenotype can be diagnosed by determining whether they possess mutations such as, for example, nonsense mutations or frameshift mutations that generate PTC by conventional methods. Alternatively, the patient can be selected by measuring the PTC-bearing gene level.
- a patient or subject to which a compound of the present invention or a pharmaceutically acceptable salt thereof is applied may be a patient or subject carrying a nonsense mutation that produces PTC.
- the NMD-associated disease of the present invention may be a disease caused by NMD due to a mutation such as a nonsense mutation or a frameshift mutation that produces PTC. Examples of several genetic diseases caused by nonsense mutations are shown in Table 1.
- 3' PTC causes mild muscular dystrophy (BMD) CFTR (Cystic fibrosis transmembrane donductance regulator gene) Differently located PTCs can cause a mild to severe phenotype, but most commonly 5' PTC: severe cystic fibrosis 3' PTC: Mild cystic fibrosis.
- BMD muscular dystrophy
- CFTR Cystic fibrosis transmembrane donductance regulator gene
- the NMD-associated genetic disorder caused by the presence of the PTC is cystic fibrosis, muscular dystrophy, autosomal dominant polycystic kidney disease (ADOKD), telangiectasia Ataxia telangiectasia, beta-thalassemia, factor VII deficiency, familial atrial fibrillation, hemophilia B, hepatic carnitine palmitoyltransferase 1A deficiency (CPT1A) ), heritable pulmonary arterial hypertension (HPAH), late infantile neuronal ceroid lipofuscinosis (LNCL), leukocyte adhesion deficiency 1 (LAD1), methylmalonic acidosis (methylmalonic academia; MMA), Hurler syndrome, nephropatic cystinosis, obesity, peroxisome biogenesis disorder (PBD), renal tubular acidosis (RTA), retinitis pigmentosa; RP), Rett syndrome (RTT), spinal muscular at
- any disease known in the art to carry a PTC-generating mutant gene is included in the scope of the NMD-related disease of the present invention.
- all diseases known in the art to have an amelioration or therapeutic effect on diseases through an NMD inhibition mechanism are also included in the scope of the NMD-related diseases of the present invention.
- the NMD-related disease that can be prevented or treated by the compound of the present invention may be muscular dystrophy, specifically, Duchenne muscular dystrophy, Becker muscular dystrophy, Ulrich's disease. (Ullrich's disease), congenital muscular dystrophy, or zone-type muscular dystrophy.
- the NMD-associated disease caused by the presence of the PTC may be cancer, in particular hereditary diffuse gastric cancer (HDGC), a cancer associated with a P53 gene mutation (eg, Li -Fraumeni syndrome, human breast cancer) or cancer associated with mutations in the APC gene (eg, colorectal cancer and familial adenomatous polyposis).
- HDGC hereditary diffuse gastric cancer
- a cancer associated with a P53 gene mutation eg, Li -Fraumeni syndrome, human breast cancer
- cancer associated with mutations in the APC gene eg, colorectal cancer and familial adenomatous polyposis.
- DMD Duchenne muscular dystrophy
- Beta-thalassemia is a blood disease that reduces hemoglobin production.
- stop codon mutations result in premature translation termination and destabilization of mRNA through nonsense mediated degradation.
- Salvatori et al. Am. J. Hematol., 84 (11): 720-8 (2009)], etc., it has been suggested that beta-thalassemia can be prevented or treated through NMD inhibition.
- composition refers to a mixture of a compound of the invention with one or more pharmaceutically acceptable carriers.
- the pharmaceutical composition facilitates administration of the compound to a patient or subject.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising the compound of the present invention or a pharmaceutically acceptable salt thereof as an active ingredient, and further comprising a pharmaceutically acceptable carrier.
- the pharmaceutically acceptable carrier may be appropriately selected by a person skilled in the art as an inactive ingredient, that is, a pharmaceutically acceptable excipient, with reference to the Handbook of Pharmaceutical Excipients and the like.
- Suitable routes of administration include, but are not limited to oral administration, parenteral administration, eg, intramuscular, intravenous, or subcutaneous administration and the like.
- mRNA is extracted from cells and the amount of mRNA is checked through RT-PCR, but this method has limitations in performing high-throughput screening (HTS). development is needed
- Beta-thalassemia (beta-thalassemia) is an NMD-related genetic disease
- beta-globin (beta-globin) is known to be related to the gene. That is, the beta-globin (beta-globin) gene of a person with thalassemia (beta-thalassemia), compared with a normal person, the PTC (premature termination codon) gene is expressed.
- a gene including a chemiluminescence gene, Renilla luciferase (RLuc), at the back of a beta-globin normal gene or PTC (premature termination codon) found in genetic diseases was inserted.
- the mRNA in the form of a normal gene inserted is not a target of NMD, whereas when a gene having PTC is inserted, it becomes a target of NMD.
- a HeLa cell line that always expresses the NMD target mRNA was prepared.
- this cell line was designed to always express the firefly luciferase (FLuc) gene, which is not a target of NMD.
- FLuc firefly luciferase
- each of the prepared cell lines was treated with caffeine, known as a non-specific NMD inhibitor, to confirm the degree of RLuc activity with respect to FLuc activity.
- caffeine known as a non-specific NMD inhibitor
- total proteins were isolated from the cells.
- the expression levels of RLuc and FLuc proteins were measured through dual luciferase assay.
- FIG. 2 it was confirmed that the expression level of RLuc in the caffeine-treated group increased by about 1,300 times to about 2000 times, compared to the caffeine-untreated group.
- HeLa cell line is suitable for performing high-throughput screening (HTS).
- HTS high-throughput screening
- Experiments were performed by optimizing conditions such as the number of cells, the amount of reagents and buffers used in a 384-well format to be suitable for HTS (Fig. 3), and NMD efficiency was measured using wortmannin, a non-specific NMD inhibitor, as a control material.
- Wortmannin is known to inhibit NMD by inhibiting SMG1-mediated UPF1 phosphorylation, a critical step in the NMD pathway (A Yamashita et al., 2001 Sep 1;15(17):2215-28). As a result, as shown in FIG.
- the wortmannin-treated group increased the expression level of RLuc by about 10-40 times (w/FF luc calibration in FIG. 3 is the RLuc value corrected for the FLuc activity value) .
- the HeLa cell line thus prepared was verified to be suitable for performing HTS as well as reflecting the efficiency of NMD well.
- RNA and protein were purified from the cells. Then, the amounts of RNA and protein were quantified through real-time PCR and dual luciferase assay. The results are shown in FIG. 4 .
- Compound 1 increased protein translation of RLuc, while compounds 2 and 3 significantly increased the amount of mRNA. From this, it was found that all three compounds exhibit an effect of inhibiting NMD, but compound 1 and compounds 2 and 3 inhibited at different stages.
- NMD is a phenomenon made through several steps of protein binding, and is particularly affected by the binding between UPF1 and UPF2 and phosphorylation of UPF1 among them (refer to Korean Patent No. 1021402, etc.).
- each compound of the present invention was specifically intended to confirm which stage of NMD acts.
- UPF1 Phosphorylation of UPF1 is known to be one of the most important factors in NMD.
- the effect of three types of compounds of the present invention on phosphorylation of UPF1 was investigated. Cells were treated with each compound at 5 ⁇ M for 12 hours, and then the total protein was purified. Thereafter, western blotting was performed using each antibody capable of recognizing Upf1 or Upf1 phosphorylated at a specific position.
- NMD is a phenomenon that occurs through several steps of protein binding, and the binding between UPF1 and UPF2 is known to be the most important step.
- the effect of the three compounds of the present invention on the binding between UPF1 and UPF2 was investigated.
- DNA expressing FLAG-UPF1 was transiently overexpressed in the cell line.
- Each compound was treated in this cell line at 5 ⁇ M for 1 hour to obtain a cell extract. Immunoprecipitation was performed on the cell extract obtained using the FLAG antibody.
- Proteins before and after immunoprecipitation were analyzed by western blotting.
- a plasmid expressing reporter mRNA and MS2 binding proteins capable of binding to the 3' UTR of the reporter mRNA were artificially expressed.
- MS2 binding proteins MS2-Upf1, MS2-Upf2, MS2-Upf3
- compounds 1 to 3 are substances that inhibit NMD in common, although there are slight differences in the level of NMD that each compound acts. Accordingly, it was confirmed that all of compounds 1 to 3 can be effectively used for the treatment of genetic diseases caused by NMD.
- DMD is a typical NMD-related genetic disease that occurs because PTC is generated in the dystrophin gene and is quickly eliminated by NMD.
- the amount of dystrophin mRNA was quantified through real-time PCR.
- DMD/GAPDH mRNA dystrophin mRNA
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
유전자 명칭 | 표현형 |
HBB (β-Globin) | 5' PTC: 열성 유전 중증 지중해성 빈혈(β-thalassaemia major); 이형접합 정상 3' PTC: 우성 유전 중간형 지중해성 빈혈 (β-thalassaemia intermedia) |
RHO (Rhodopsin) | 5' PTC: 열성 유전 실명(blindness); 이형접합은 망막도(retinogram)에 비정상을 가지나, 임상적 질환은 아님 3' PTC: 우성 유전 실명 |
SOX 10 (SRY-box 10) | 5' PTC: 선천성 신경감각 난청 (neurosensory deafness) 및 결장 신경절증 (colonic agangliosis)을 유발하는 반가불충분성 (haploinsufficiency) 3' PTC: 신경감각 난청, 결장 신경절증, 말초 신경병증 (peripheral neuropathy) 및 중추성 수초이상 백질영양증 (central dysmyelinating leukodystrophy)을 포함하는 우성 유전 신경발달 결함 |
IFNGR1 (Interferon-γ receptor 1) | 5' PTC: 우성 유전 마이코박테리아 감염에 대한 감수성; 이형접합 정상 3' PTC: 우성 유전 마이코박테리아 감염에 대한 감수성 |
CRX (Cone-rod homeobox containing gene) | 5' PTC: 현재까지 동형접합 없음; 이형접합 정상 3' PTC: 우성 유전 Leber 선천성 흑내장 (amaurosis) |
ROR2 (Receptor tyrosine kinase-like orphan receptor 2) | 5' PTC: 열성 유전 Robinow 증후군 (orodental abnormalities, hypoplastic genitalia, multiple rib/vertebral anomalies); 이형접합 정상 3' PTC: 우성 유전 B형 단지증 (shortening of digits and metacarpals) |
CLCN1 (Chloride channel 1, skeletal muscle) | 5' PTC: 열성 유전 Becker 병 3' PTC: 우성 유전 Thomsen 병 (muscular disorder characterized by muscle stiffness and an inability of the muscle to relax) |
VWF (von willebrand factor) | 5' PTC: 열성 유전 3형 von willebrand 병; 이형접합 정상 3' PTC: 우성 유전 2A 3형 von willebrand 병 |
F10 (Coagulation factor X) | 5' PTC: 열성 유전 출혈성 소인 (bleeding tendency); 이형접합 정상 3' PTC: 우성 유전 출혈성 소인 |
MPN (Myelin protein zero) | 5' PTC: 반가불충분성, Charcol-Marie-Tooth 병 (neuropathy with loss of muscle tissue and touch sensation) 3' PTC: 우성 음성 또는 기능 획득 (gain-of-function), 선천성 저수초성 신경병증 (hypomyelinating neuropathy) |
ELN (Elastin) | 5' PTC: 반가불충분성, 판막상 대동맥 협착증 (supravalvular aortic stenosis), 판막 심장병 (valvular heart disease) 3' PTC: 우성 음성 또는 기능 획득, 선천성 각막염 (congenital cutis laxa), 결합조직 장애 |
COL1A1 (Collagen type I, α1) | 5' PTC: 우성 유전, 1형 골형성부전증 (osteogenesis imperfecta (OI) type I) (경증형) 3' PTC: 2형-4형 OI (중증형) |
ATM (Ataxia-telangiectsia mutated gene) | 5' PTC: 경증형 운동실조증 (ataxia) 3' PTC: 생존 시간이 짧은 중증형 |
SMN1 (Survival motor neuron gene) | 5' PTC: 3형 척수 근위축증 (spinal muscular atrophy (SMA) type III) (경증형) 3' PTC: 1형 척수 근위축증 (SMA type I) (중증형) |
DMD (Dystrophin) | 상이한 위치에 있는 PTC는 경증 내지 중증 표현형을 야기할 수 있으나, 가장 흔하게 5' PTC는 중증의 근이영양증 (muscular dystophy (DMD))을 야기함 3' PTC는 경증의 근이영양증 (muscular dystrophy (BMD))을 야기함 |
CFTR (Cystic fibrosis transmembrane donductance regulator gene) | 상이한 위치에 있는 PTC는 경증 내지 중증 표현형을 야기할 수 있으나, 가장 흔하게는 5' PTC: 중증의 낭포성 섬유증 (cystic fibrosis) 3' PTC: 경증의 낭포성 섬유증. NMD가 비효율적인 환자는 넌센스 억제 치료에 더 잘 반응함 |
PAX6 (Paired box gene 6) | 5' PTC: 무홍채증 (aniridia), 홍채의 선천적 결핍 3' PTC: 검출되지 않았으나, 우성 음성 단백질은 심각한 표현형을 보일 것으로 예측됨 |
EDAR (Ectodysplasin-A receptor gene) | 5' PTC: 상염색체 열성 HED (hypohidrotic ectodermal dysplasia) 3' PTC: 상염색체 우성 HED |
SCNN1B (Beta subunit of sodium channel) | 5' PTC: 상염색체 열성 PHA1 (pseudohypoaldosteronism I) 3' PTC: 우성 Liddle 증후군 |
Claims (8)
- 제1항에 있어서, 상기 화합물 또는 그의 제약상 허용되는 염은 넌센스-매개 mRNA 분해(NMD)를 억제하는 것인, 약학 조성물.
- 제1항에 있어서, 상기 화합물 또는 그의 제약상 허용되는 염은 UPF1의 인산화를 저해하는 것인, 약학 조성물.
- 제1항에 있어서, 상기 질병은 넌센스 돌연변이 또는 프레임시프트 돌연변이와 연관된 미성숙 종결 코돈(PTC)으로 인한 NMD에 의해 유발되는 유전 질병인 것인, 약학 조성물.
- 제4항에 있어서, 상기 미성숙 종결 코돈(PTC)으로 인한 NMD에 의해 유발되는 유전 질병은 낭포성 섬유증(cystic fibrosis), 근이영양증, 상염색체 우성 다낭성 신장질환(autosomal dominant polycystic kidney disease; ADOKD), 모세혈관확장성운동실조증(ataxia telangiectasia), 베타-지중해성 빈혈(beta-thalassemia), 인자 VII 결핍증(factor VII deficiency), 가족성 심방 세동, 혈우병 B, 간의 카르니틴 팔미토일 전달 효소 1A 결핍증(hepatic carnitine palmitoyltransferase 1A deficiency; CPT1A), 유전성 폐 동맥 고혈압(heritable pulmonary arterial hypertension; HPAH), 후기 영아 신경원성 세로이드 리포푸신증(late infantile neuronal ceroid lipofuscinosis; LNCL), 백혈구 부착 결핍1(leukocyte adhesion deficiency 1; LAD1), 메틸말론산증(methylmalonic academia; MMA), 헐러 증후군(Hurler syndrome), 신세포성 시스틴증(nephropatic cystinosis), 비만, 퍼옥시좀 형성 장애(peroxisome biogenesis disorder; PBD), 신세뇨관 산증 (RTA), 망막색소 변성증(retinitis pigmentosa; RP), 레트 증후군(Rett syndrome; RTT), 척수 근위축증(spinal muscular atrophy; SMA), 스티뷰-와이드만 증후군(Stuve-Wiedemann syndrome; SMS), X-연관 신성요붕증(X-linked nephrogenic diabetes insipidus; XNDI) 또는 어셔 증후군(Usher syndrome; USH1)인, 약학 조성물.
- 제5항에 있어서, 상기 근이영양증은 듀센형 근이영양증(Duchenne muscular dystrophy), 백커형 근위측증(Becker muscular dystrophy), 울리히병(Ullrich's disease), 선천성 근위축증 근이영양증, 또는 지대형 근육 근이영양증인, 약학 조성물.
- 제4항에 있어서, 상기 미성숙 종결 코돈(PTC)으로 인한 NMD에 의해 유발되는 유전 질병은 유전적 확산성 위암(hereditary diffuse gastric cancer; HDGC), P53 유전자 돌연변이와 관련된 암, 또는 APC 유전자 돌연변이와 관련된 암인, 약학 조성물.
- 제1항에 있어서, 제약상 허용되는 담체를 추가로 포함하는 약학 조성물.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/277,289 US20240156805A1 (en) | 2021-02-16 | 2022-02-15 | Compound for inhibiting nonsense-mediated mrna decay |
EP22756467.1A EP4295850A1 (en) | 2021-02-16 | 2022-02-15 | Compound for inhibiting nonsense-mediated mrna decay |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2021-0020750 | 2021-02-16 | ||
KR20210020750 | 2021-02-16 | ||
KR10-2021-0111192 | 2021-08-23 | ||
KR1020210111192A KR102378381B1 (ko) | 2021-08-23 | 2021-08-23 | 넌센스-매개 mRNA 분해를 억제하기 위한 화합물 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022177269A1 true WO2022177269A1 (ko) | 2022-08-25 |
Family
ID=82931486
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/002228 WO2022177269A1 (ko) | 2021-02-16 | 2022-02-15 | 넌센스-매개 mrna 분해를 억제하기 위한 화합물 |
PCT/KR2022/002226 WO2022177267A1 (ko) | 2021-02-16 | 2022-02-15 | 넌센스-매개 mrna 분해를 억제하기 위한 화합물 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/002226 WO2022177267A1 (ko) | 2021-02-16 | 2022-02-15 | 넌센스-매개 mrna 분해를 억제하기 위한 화합물 |
Country Status (3)
Country | Link |
---|---|
US (2) | US20240156805A1 (ko) |
EP (2) | EP4295850A1 (ko) |
WO (2) | WO2022177269A1 (ko) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006122806A2 (en) | 2005-05-20 | 2006-11-23 | Novartis Ag | 1,3-dihydro-imidazo [4,5-c] quinolin-2-ones as lipid kinase inhibitors |
WO2008144463A1 (en) | 2007-05-18 | 2008-11-27 | Smithkline Beecham Corporation | Quinoline derivatives as pi3 kinase inhibitors |
KR101021402B1 (ko) | 2008-05-08 | 2011-03-14 | 고려대학교 산학협력단 | 유전자 pnrc2를 이용한 nmd 조절 방법 |
WO2012052730A1 (en) * | 2010-10-21 | 2012-04-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Use of pi3k inibitors for the treatment of obesity, steatosis and ageing |
WO2020060779A2 (en) * | 2018-09-07 | 2020-03-26 | Cornell University | Methods and compositions for treating laminopathies affecting skeletal or cardiac muscle |
WO2020168241A1 (en) * | 2019-02-15 | 2020-08-20 | Flagship Pioneering Inc. | X-reactivation modulators and uses thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2073805T3 (pl) * | 2006-10-12 | 2015-08-31 | Ptc Therapeutics Inc | Sposoby dawkowania 1,2,3-oksadiazolu aktywnego po podaniu doustnym w terapii supresyjnej mutacji nonsensownej |
KR20160108814A (ko) * | 2015-03-06 | 2016-09-20 | 한국과학기술원 | mTOR 억제제를 포함하는 난치성 뇌전증의 예방 또는 치료용 조성물 |
KR20170076606A (ko) * | 2015-12-23 | 2017-07-04 | 연세대학교 산학협력단 | Upf1 억제제를 유효성분으로 포함하는 면역치료용 약제학적 조성물 |
-
2022
- 2022-02-15 US US18/277,289 patent/US20240156805A1/en active Pending
- 2022-02-15 WO PCT/KR2022/002228 patent/WO2022177269A1/ko active Application Filing
- 2022-02-15 EP EP22756467.1A patent/EP4295850A1/en active Pending
- 2022-02-15 EP EP22756465.5A patent/EP4295849A1/en active Pending
- 2022-02-15 WO PCT/KR2022/002226 patent/WO2022177267A1/ko active Application Filing
- 2022-02-15 US US18/277,304 patent/US20240139183A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006122806A2 (en) | 2005-05-20 | 2006-11-23 | Novartis Ag | 1,3-dihydro-imidazo [4,5-c] quinolin-2-ones as lipid kinase inhibitors |
WO2008144463A1 (en) | 2007-05-18 | 2008-11-27 | Smithkline Beecham Corporation | Quinoline derivatives as pi3 kinase inhibitors |
KR101021402B1 (ko) | 2008-05-08 | 2011-03-14 | 고려대학교 산학협력단 | 유전자 pnrc2를 이용한 nmd 조절 방법 |
WO2012052730A1 (en) * | 2010-10-21 | 2012-04-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Use of pi3k inibitors for the treatment of obesity, steatosis and ageing |
WO2020060779A2 (en) * | 2018-09-07 | 2020-03-26 | Cornell University | Methods and compositions for treating laminopathies affecting skeletal or cardiac muscle |
WO2020168241A1 (en) * | 2019-02-15 | 2020-08-20 | Flagship Pioneering Inc. | X-reactivation modulators and uses thereof |
Non-Patent Citations (10)
Title |
---|
CAI JIAJING, XIA JINGRUO, ZOU JIANG, WANG QIANG, MA QIANG, SUN RU, LIAO HEBIN, XU LEI, WANG DONGSHENG, GUO XIAOLAN: "The PI3K/mTOR dual inhibitor NVP‐BEZ235 stimulates mutant p53 degradation to exert anti‐tumor effects on triple‐negative breast cancer cells", FEBS OPEN BIO, ELSEVIER, US, vol. 10, no. 4, 1 April 2020 (2020-04-01), US , pages 535 - 545, XP055960647, ISSN: 2211-5463, DOI: 10.1002/2211-5463.12806 * |
CHEN ZHE, LI LEI, WU WEIRU, LIU ZHILONG, HUANG YONGXIU, YANG LI, LUO QING, CHEN JIEPING, HOU YU, SONG GUANBIN: "Exercise protects proliferative muscle satellite cells against exhaustion via the Igfbp7-Akt-mTOR axis", THERANOSTICS, IVYSPRING INTERNATIONAL PUBLISHER, AU, vol. 10, no. 14, 1 January 2020 (2020-01-01), AU , pages 6448 - 6466, XP055960645, ISSN: 1838-7640, DOI: 10.7150/thno.43577 * |
HOLBROOK ET AL., NATURE GENETICS, vol. 36, 2004, pages 801 - 808 |
KARAM ET AL., ONCOGENE, vol. 27, 2008, pages 4255 - 4260 |
KHAJAVI ET AL., EUR J HUM GENET., vol. 14, 2006, pages 1074 - 1081 |
MILLERPEARCE, MUTAT RES REV MUTAT RES., vol. 762, 2014, pages 52 - 64 |
SALVATORI ET AL., AM. J. HEMATOL., vol. 84, no. 11, 2009, pages 720 - 8 |
SUPEK ET AL., TRENDS GENET., vol. 37, 2021, pages 657 - 668 |
USUKI ET AL., MOLECULAR THERAPY, vol. 14, 2006, pages 351 - 360 |
WELCH ET AL., NATURE, vol. 447, 2007, pages 87 - 91 |
Also Published As
Publication number | Publication date |
---|---|
WO2022177267A1 (ko) | 2022-08-25 |
US20240139183A1 (en) | 2024-05-02 |
EP4295850A1 (en) | 2023-12-27 |
EP4295849A1 (en) | 2023-12-27 |
US20240156805A1 (en) | 2024-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2428210B1 (en) | P38 mapk inhibitors for use in treating ocular hypertension | |
WO2000004187A9 (en) | Methods and kits for diagnosing and determination of the predisposition of diseases | |
EP2606884A1 (en) | Inhibitors of notch signaling pathway and use thereof in treatment of cancers | |
US10426782B2 (en) | Pharmaceutical formulations of a pan-RAF kinase inhibitor and processes for their preparation | |
US20220152041A1 (en) | Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomapathies | |
WO2008131439A1 (en) | Treatment and/or prevention of presbycusis by modulation of metabotropic glutamate receptor 7 | |
WO2022177269A1 (ko) | 넌센스-매개 mrna 분해를 억제하기 위한 화합물 | |
WO2019009674A1 (ko) | 아데노신 유도체를 포함하는 당뇨병성 신증 예방 및 치료용 약학적 조성물 | |
US20190117596A1 (en) | Ty-52156 compounds for the treatment of cancer | |
Kirchgessner et al. | Detection of the 5‐HT1A receptor and 5‐HT1A receptor mRNA in the rat bowel and pancreas: Comparison with 5‐HT1Preceptors | |
AU2018303109B2 (en) | Use of aminoalkylbenzothiazepine derivatives | |
KR102378381B1 (ko) | 넌센스-매개 mRNA 분해를 억제하기 위한 화합물 | |
EP2628482A1 (en) | Rho kinase inhiitors for use in the treatment of neuroblastoma | |
Cacabelos et al. | Epigenetics and pharmacoepigenetics of age-related neurodegenerative disorders | |
TW202327589A (zh) | 肝病之組合療法 | |
WO2022114881A1 (ko) | 벤즈브로마론을 포함하는 상처 또는 흉터의 예방 또는 치료용 약학 조성물 | |
WO2021125762A1 (ko) | 혈뇌장벽 투과능을 가지는 펩티드 핵산 복합체를 유효성분으로 함유하는 치매 예방 또는 치료용 조성물 | |
WO2022030879A1 (ko) | 페닐알킬 카바메이트 화합물을 포함하는 kca3.1채널 매개질환 치료용 조성물 | |
WO2021091009A1 (ko) | 알오알알파를 표적으로 하는 염증성 장질환 치료제 스크리닝 방법 | |
WO2022065939A1 (ko) | 스핑고신-1-인산 수용체 효능제의 용도 | |
WO2023200122A1 (ko) | Rage 길항제 및 age 소거제를 포함하는 당뇨성 뇌졸중 예방 또는 치료용 약학적 조성물 | |
WO2024080651A1 (ko) | Thada 마커를 이용한 설폰요소제 의존성 예측용 조성물 및 그 예측 방법 | |
WO2020242225A1 (ko) | IRE1α 키나아제 활성화제를 유효성분으로 포함하는 단백질 형태 이상 질환의 예방 또는 치료용 조성물 | |
WO2022245131A1 (ko) | Parp 저해제 저항성 암 치료제 | |
WO2023277502A1 (ko) | 암의 예방 또는 치료용 약학 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22756467 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18277289 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022756467 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022756467 Country of ref document: EP Effective date: 20230918 |